High-throughput identification of genes involved in single and multi-drug resistance in pancreatic cancer with pooled CRISPR screening
Pancreatic ductal adenocarcinoma (PDAC) patients suffer poor outcomes in part due to therapeutic resistance. We conducted four genome-wide CRISPR activation (CRISPRact) and CRISPR knock out (CRISPRko) screens to identify novel resistance mechanisms to four cytotoxic chemotherapies (gemcitabine, 5-fluorouracil, irinotecan, and oxaliplatin). ABCG2, a well-described efflux pump was the strongest mediator of resistance. We showed that overexpressing HDAC1 altered promoter occupancy and expression of genes involved in the epithelial-to-mesenchymal transition. Using the results of our CRISPR screens, we predicted drug sensitivity for patients and cell lines based on gene expression profiles. These predictions could be clinically useful for treatment selection.